Safety and Improved Clinical Outcomes in Patients Treated With New Equine-Derived Heptavalent Botulinum Antitoxin
Current Language EN
English English Türkçe Türkçe Español Español Português Português Pусский Pусский Filipino Filipino Tiếng Việt Tiếng Việt हिन्दी हिन्दी العربية العربية বাংলা বাংলা Deutsch Deutsch 中文 中文

Safety and Improved Clinical Outcomes in Patients Treated With New Equine-Derived Heptavalent Botulinum Antitoxin

Yu, Patricia A;Lin, Neal H;Mahon, Barbara E;Sobel, Jeremy;Yu, Yon;Mody, Rajal K;Gu, Weidong;Clements, Jennifer;Kim, Hye-Joo;Rao, Agam K;
clinical infectious diseases 2018 Vol. 66 pp. S57-S64
80
a2018clinicalsafety

Abstract

Based on patient experience of equine-derived heptavalent botulinum antitoxin (HBAT), botulism patients treated with HBAT within 2 days of symptom onset had sho

Keywords

Access

URL:
https://doi.org/10.1093/cid/cix816

Citation

ID: 268921
Ref Key: a2018clinicalsafety
Use this key to autocite in SciMatic or Thesis Manager

References

References

No Bibliography

Blockchain Verification

Account:
NFT Contract Address:
0x95644003c57E6F55A65596E3D9Eac6813e3566dA
Article ID:
268921
Unique Identifier:
Network:
Scimatic Chain (ID: 481)
Blockchain Readiness Checklist
Authors
Abstract
Journal Name
Year
Title
5/5
Creates 1,000,000 NFT tokens for this article
Token Features:
  • ERC-1155 Standard NFT
  • 1 Million Supply per Article
  • Transferable via MetaMask
  • Permanent Blockchain Record
Blockchain QR Code
Scan with Saymatik Web3.0 Wallet
Gas fees required in SCI Coins
Buy SCI

Saymatik Web3.0 Wallet

Google Play
App Store